tetrahydrouridine
Small moleculeexperimental
Clinical trial activity
14 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
11
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 1999 (NCT00359606)
Timeline
Indications
Studied for
- Anemia, Sickle Cell · Phase 2
- Brain Neoplasms · Phase 1
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 2
- Healthy Volunteers · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lung Neoplasms · Phase 2
- Lymphoma, B-Cell · Early Phase 1
- Lymphoma, Non-Hodgkin · Early Phase 1
- Lymphoma, T-Cell · Early Phase 1
- Melanoma · Phase 1
- Mesothelioma, Malignant · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Neoplasms, Germ Cell and Embryonal · Phase 1
- Pancreatic Neoplasms · Early Phase 1
- Sarcoma · Phase 1
- Urinary Bladder Neoplasms · Phase 2
Mechanism of action
- DNAINHIBITOR
DNA inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O- Mol. weight
- 248.24 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2311128 ↗
- ChEMBLCHEMBL1236475 ↗
Also known as
- tetrahydrouridine
- tetrahydrouridine
- tetrahydrouridine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05816356 | Phase 1 | Mar 24, 2023 | EpiDestiny, Inc., Worldwide Clinical Trials |
| NCT05405114 | Phase 2 | Jul 7, 2022 | Novo Nordisk |
| NCT03233724 | Phase 1/Phase 2 (Phase 2) | Apr 11, 2018 | National Cancer Institute (NCI) |
| NCT02664181 | Phase 2 | Jun 30, 2017 | Case Western Reserve University, University of Rochester |
| NCT02846935 | Early Phase 1 (Phase 1) | Apr 25, 2017 | Case Western Reserve University, University of Rochester |
| NCT02847000 | Early Phase 1 (Phase 1) | Dec 20, 2016 | Case Western Reserve University, University of Rochester |
| NCT02839694 | Phase 1 | Jul 7, 2016 | National Cancer Institute (NCI) |
| NCT01685515 | Phase 1 | Aug 1, 2012 | University of Illinois at Chicago, University of Rochester |
| NCT01534598 | Phase 1 | Jan 20, 2012 | National Cancer Institute (NCI) |
| NCT01041443 | Phase 1 | Dec 1, 2009 | City of Hope National Medical Center |
| NCT00978250 | Phase 2 | Aug 20, 2009 | National Cancer Institute (NCI) |
| NCT00521183 | Phase 1 | Jun 1, 2007 | University of Miami |
| NCT00077051 | Phase 1 | Apr 1, 2004 | National Cancer Institute (NCI), University of Miami |
| NCT00359606 | Phase 1 | Apr 1, 1999 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 6 | 4 | 2 | 1999 |
| University of Rochester | Academic/Hospital | 4 | 1 | 2 | 2012 |
| Case Western Reserve University | Academic/Hospital | 3 | 3 | 2 | 2016 |
| City of Hope National Medical Center | Academic/Hospital | 2 | 2 | 1 | 1999 |
| University of Miami | Academic/Hospital | 2 | 2 | 1 | 2004 |
| EpiDestiny, Inc. | For profit | 1 | 1 | 1 | 2023 |
| Novo Nordisk | For profit | 1 | 1 | 1 | 2022 |
| University of Illinois at Chicago | Academic/Hospital | 1 | 0 | 1 | 2012 |
| Worldwide Clinical Trials | For profit | 1 | 0 | 1 | 2023 |
9 organizations
Page 1 / 1